Uwe Rix
Impact in
- Pharmacology top 1%
- Microbial Natural Products and Biosynthesis
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments
Papers in
- Spectroscopy 17
- Advanced Proteomics Techniques and Applications 17
- Hematology 15
- Chronic Myeloid Leukemia Treatments 13
- Co-authors
- Giulio Superti‐Furga (32 shared papers)Lily L. Remsing Rix (33 shared papers)Oliver D. Hantschel (6 shared papers)Keiryn L. Bennett (21 shared papers)Jacques Colinge (18 shared papers)Jürgen Rohr (12 shared papers)Peter Valent (15 shared papers)Eric B. Haura (31 shared papers)
- Journals
- Blood (9 papers)Molecular Cancer Therapeutics (6 papers)Nature Chemical Biology (5 papers)Cancer Research (5 papers)Journal of Proteome Research (4 papers)
- Partner nations
- United StatesAustriaGermany
In The Last Decade
Uwe Rix
98 papers receiving 5.4k citations
Uwe Rix's Hit Papers
Peers
Comparison fields: 5 of 100
- Pharmacology 806
- Hematology 670
- Spectroscopy 616
- Computational Theory and Mathematics 497
- Oncology 647
Countries citing papers authored by Uwe Rix
This map shows the geographic impact of Uwe Rix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe Rix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe Rix more than expected).
Fields of papers citing papers by Uwe Rix
This network shows the impact of papers produced by Uwe Rix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe Rix. The network helps show where Uwe Rix may publish in the future.
Co-authors
The 25 scholars most cited alongside Uwe Rix, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 98 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Hit paper breakdown → | 2007 | 579 |
| 2 | Target profiling of small molecules by chemical proteomics Hit paper breakdown → | 2008 | 499 |
| 3 | 2007 | 255 | |
| 4 | 2008 | 248 | |
| 5 | 2010 | 242 | |
| 6 | 2002 | 229 | |
| 7 | 2008 | 217 | |
| 8 | 2019 | 129 | |
| 9 | 2017 | 128 | |
| 10 | 2003 | 122 | |
| 11 | 2013 | 100 | |
| 12 | 2011 | 95 | |
| 13 | 2009 | 90 | |
| 14 | 2012 | 86 | |
| 15 | 2021 | 85 | |
| 16 | 2016 | 84 | |
| 17 | 2004 | 80 | |
| 18 | 2013 | 80 | |
| 19 | 2019 | 79 | |
| 20 | 2000 | 78 |
About Uwe Rix
Uwe Rix is a scholar working on Spectroscopy, Hematology, Pulmonary and Respiratory Medicine, Pharmacology and Oncology, having authored 98 papers that have together received 5.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (23 papers), Advanced Proteomics Techniques and Applications (17 papers), Chronic Myeloid Leukemia Treatments (13 papers), Microbial Natural Products and Biosynthesis (12 papers), Computational Drug Discovery Methods (9 papers), Cancer Mechanisms and Therapy (6 papers), Mast cells and histamine (5 papers) and Melanoma and MAPK Pathways (5 papers). The work is most often cited by research in Pharmacology (806 citations), Hematology (670 citations), Spectroscopy (616 citations), Computational Theory and Mathematics (497 citations) and Oncology (647 citations). Uwe Rix has collaborated with scholars based in United States, Austria and Germany. Frequent co-authors include Giulio Superti‐Furga, Lily L. Remsing Rix, Oliver D. Hantschel, Keiryn L. Bennett, Jacques Colinge, Jürgen Rohr, Peter Valent, Eric B. Haura, John M. Koomen and Bin Fang. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Nature Chemical Biology, Cancer Research and Journal of Proteome Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.